Publications by authors named "David B Turner"

Claim this Profile
G
Gastrointestinal Bile Salt Concentrations in Healthy Adults Under Fasted and Fed Conditions: A Systematic Review and Meta-Analysis for Mechanistic Physiologically-Based Pharmacokinetic (PBPK) Modelling.
Laura G Al-Amiry Santos, Helen Musther, Neeru Bala, Neel Deferm, Gaurangkumar Patel, David B Turner

AAPS J· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optically Transparent Lead Halide Perovskite Polycrystalline Ceramics.
Michael C Brennan, Christopher L McCleese, Lauren M Loftus, Jeremiah Lipp, Michael Febbraro, David B Turner

ACS Appl Mater Interfaces· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Dose-Exposure-Response Relationships of Miltefosine in Adults and Children using Physiologically-Based Pharmacokinetic Modeling Approach.
Shadrack J Madu, Ke Wang, Siri Kalyan Chirumamilla, David B Turner, Patrick G Steel

Pharm Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Biopharmaceutics Model (PBBM) of Minimally Absorbed Locally Acting Drugs in the Gastrointestinal Tract-Case Study: Tenapanor.
Konstantinos Stamatopoulos, Nena Mistry, Nikoletta Fotaki, David B Turner, Brandon Swift

Pharmaceutics· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging the use of in vitro and computational methods to support the development of enabling oral drug products: An InPharma commentary.
Christos Reppas, Martin Kuentz, Annette Bauer-Brandl, Sara Carlert, André Dallmann, David B Turner

Eur J Pharm Sci· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug.
Farzaneh Salem, Ali Nimavardi, Jennypher Mudunuru, Debra Tompson, Jackie Bloomer, David B Turner

CPT Pharmacometrics Syst Pharmacol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-specific binding of compounds in metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models.
Iain Gardner, Mandy Xu, Chunyan Han, Yi Wang, Xingjin Jiao, David B Turner

Xenobiotica· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
Sumit Arora, Amita Pansari, Peter J Kilford, Masoud Jamei, David B Turner

Eur J Drug Metab Pharmacokinet· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series.
Mark McAllister, Talia Flanagan, Susan Cole, Andreas Abend, Evangelos Kotzagiorgis, David B Turner

Pharmaceutics· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artemisinin Cocrystals for Bioavailability Enhancement. Part 2: Bioavailability and Physiologically Based Pharmacokinetic Modeling.
Manreet Kaur, Vanessa Yardley, Ke Wang, Jinit Masania, Randolph R J Arroo, David B Turner

Mol Pharm· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic PBPK Modelling to Predict the Advantage of the Salt Form of a Drug When Dosed with Acid Reducing Agents.
Siri Kalyan Chirumamilla, Venkatesh Teja Banala, Masoud Jamei, David B Turner

Pharmaceutics· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the impact of acid-reducing agents on drug absorption using biorelevant in vitro tools and PBPK modeling - case example dipyridamole.
Domagoj Segregur, Richard Barker, James Mann, Andrea Moir, Eva M Karlsson, David B Turner

Eur J Pharm Sci· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
Masoud Jamei, Bertil Abrahamsson, Jonathan Brown, Jan Bevernage, Michael B Bolger, David B Turner

Eur J Pharm Biopharm· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biopharmaceutic Extrapolation (IVIV_E) Informed Physiologically-Based Pharmacokinetic Model of Ritonavir Norvir Tablet Absorption in Humans Under Fasted and Fed State Conditions.
Sumit Arora, Amita Pansari, Peter Kilford, Masoud Jamei, Iain Gardner, David B Turner

Mol Pharm· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining biorelevant in vitro and in silico tools to investigate the in vivo performance of the amorphous solid dispersion formulation of etravirine in the fed state.
Chara Litou, David B Turner, Nico Holmstock, Jens Ceulemans, Karl J Box

Eur J Pharm Sci· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-Based PBPK Model for the Prediction of Time-Variant Bile Salt Disposition within GI Luminal Fluids.
Konstantinos Stamatopoulos, Shriram M Pathak, Luca Marciani, David B Turner

Mol Pharm· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
Ioannis Loisios-Konstantinidis, Rodrigo Cristofoletti, Nikoletta Fotaki, David B Turner, Jennifer Dressman

Eur J Pharm Sci· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states.
Chara Litou, Nikunjkumar Patel, David B Turner, Edmund Kostewicz, Martin Kuentz

Eur J Pharm Sci· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.
Devendra Pade, Masoud Jamei, David B Turner, Bipin Mistry, Marilyn N Martinez

Eur J Pharm Biopharm· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biopharmaceutic IVIVE-Mechanistic Modeling of Single- and Two-Phase In Vitro Experiments to Obtain Drug-Specific Parameters for Incorporation Into PBPK Models.
Shriram M Pathak, Kerstin Julia Schaefer, Masoud Jamei, David B Turner

J Pharm Sci· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
Shriram M Pathak, Aaron Ruff, Edmund S Kostewicz, Nikunjkumar Patel, David B Turner

Mol Pharm· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
Bart Hens, Shriram M Pathak, Amitava Mitra, Nikunjkumar Patel, Bo Liu, David B Turner

Mol Pharm· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model.
Helen Musther, Matthew D Harwood, Jiansong Yang, David B Turner, Amin Rostami-Hodjegan

J Pharm Sci· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs.
Rachel H Rose, David B Turner, Sibylle Neuhoff, Masoud Jamei

AAPS J· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on "In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically-Based Absorption Models".
David B Turner, Bo Liu, Nikunjkumar Patel, Shriram M Pathak, Sebastian Polak

Mol Pharm· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis